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Abstract
Background: Human cancer cells maintain telomeres to protect cells from senescence through telomerase activity (TA) or
alternative lengthening of telomeres (ALT) in different cell types. Moreover, cellular senescence can be bypassed by
Epithelial-to-mesenchymal transition (EMT) during cancer progression in diverse solid tumors. However, it has not been
elucidated the characteristics of telomere maintenance and progression ability after long-term culture in bladder cancer T24
cells with hTERT dysfunction.
Methodology/Principal Findings: In this study, by using a dominant negative mutant human telomerase reverse
transcriptase (hTERT) vector to inhibit TA in bladder cancer T24 cells, we observed the appearance of long phenotype of
telomere length and the ALT-associated PML body (APB) complex after the 27
th passage, indicating the occurrence of ALT-
like pathway in surviving T24/DN868A cells with telomerase inhibition. Meanwhile, telomerase inhibition resulted in
significant EMT as shown by change in cellular morphology concomitant with variation of EMT markers. Consistently, the
surviving T24/DN868A cells showed increased progression ability in vitro and in vivo. In addition, we found Twist was
activated to mediate EMT in surviving T24/DN868A samples.
Conclusions/Significance: Taken together, our findings indicate that bladder cancer T24 cells may undergo the telomerase-
to-ALT-like conversion and promote cancer progression at advanced stages through promoting EMT, thus providing novel
possible insight into the mechanism of resistance to telomerase inhibitors in cancer treatment.
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Introduction
The stabilization of telomere is critical for the infinite cellular
proliferation which is necessary for tumor formation [1]. At least
two mechanisms have been identified to maintain telomere
homeostasis in cells in vivo as well as in vitro. First, most carcinoma
cells utilize telomerase, a multi-subunit cellular ribonucleoprotein
enzyme (referred to as a telomerase pathway), to add telomeric
repeats onto chromosome ends [2]. Telomerase is composed of an
RNA subunit, telomerase-associated protein 1, and the catalyst
telomerase reverse transcriptase (hTERT), which is a limiting
component in regulating the activity of telomerase [3]. Second,
sarcoma cells utilize a telomerase-independent mechanism termed
alternative lengthening of telomeres (i.e., ALT pathway) to
maintain chromosome termini [4]. The onset of ALT is
determined by the appearance of long, heterogeneous telomere
length, and the appearance of ALT-associated promyelocytic
leukemia bodies (APBs) in about 10% of interphase nuclei [5].
Previous reports have indicated that telomerase and the ALT
mechanism could coexist in some tumors [4,6]. Furthermore, a
reversible conversion of telomerase-positive to telomerase-negative
cells has been reported in cases of human papillomavirus type 16
E6-immortalized fibroblasts [7]. In view of the importance of
telomerase in cell immortalization and lack of telomerase
expression in most normal somatic cells, telomerase inhibitors
held considerable promise for cancer therapy in the past [8]. But
the possibility of activation of ALT which is resistant to telomerase
inhibitors complicates this situation [9]. It is well known that ALT
confers properties different from telomerase on cancer malignan-
cy. In the case of glioblastoma multiforme, ALT correlated with a
better patient prognosis [10], whereas a poor prognosis was
detected in patients with liposarcoma [11]. The reason for the
difference of cancer malignancy remains elusive.
In addition to telomere maintenance, the acquisition of a fully
malignant phenotype also includes the requirement of metastasis.
Epithelial-to-mesenchymal transition (EMT) plays an important
role in the progression of primary tumors toward to metastases
[12]. Recent observations suggest that EMT and cell senescence
are crossed in cancer progression [13]. Several distinct transcrip-
tion factors, which have been found to be capable of inducing
EMT programs, such as Twist and ZEB1, can also protect cells
from senescence induced by the ras oncogene [14,15].
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27748In this work, we used a dominant negative mutant of hTERT to
constitutively inactivate telomerase activity (TA) in bladder cancer
T24 cells. Our data show that long telomere length and APBs
complex without the up-regulation of TA can occur during long-
term culture in bladder cancer cells in vitro. Strikingly, a cross
between EMT and telomere maintenance pathway was observed
concomitantly with increased progression ability. Furthermore,
Twist was activated to induce EMT. In summary, we describe a
novel mechanism in the acquisition of invasive features and
telomere homeostasis after telomerase inhibition in bladder cancer
T24 cells, thus providing insight into drug resistance after
telomerase inhibition in bladder cancer.
Methods
Ethics Statement
All experiments on the animals conform to the Guidelines of
Animal Care of Xi’an Jiaotong University and approved by the
Ethical Review Board (ERB) committee (The First Affiliated
Hospital of Medical College, Xi’an Jiaotong University, China),
and the approval ID of the ethic board is SCXK2007-0005.
Antibodies
Antibodies against PML, TRF2, N-cad, Vimentin, Cytokeratin-
18, 19 (CK-18, CK-19), Matrix metalloproteinases-2 (MMP-2) and
Twist were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Cell culture
The human bladder cancer cell line T24 and osteosarcoma cell
line U2OS were cultured in Dulbecco’s modified Eagle’s Medium
(GIBCO, Grand Island, NY) supplemented with 10% (v/v) fetal
bovine serum (FBS, Sijiqing, Hangzhou, China) at 37uC with 5%
CO2 in a humidified incubator.
Establishment of hTERT
DN868A Stable cells and transient
Twist transfection
The dominant negative mutant construct of hTERT (PCI-neo-
hTERT
DN868A) was verified by sequencing before transfection into
cultured T24 cells. siRNA for Twist were designed and synthesized
by Invitrogen (Shanghai, China). The sequence of siTwist was:
sense 59-CACCGGACAAGCUGAGCAAGAUUCACGAAUG-
AAUCU UGCUCAGCUUGUCC-39; antisense 59-AAAAGGA-
CAAGCUGAGCAAGAUUCA UUCGUGAAUCUUGCUCA-
GCUUGUCC-39. Transfection was carried out using LipofectA-
MINE 2000 (Invitrogen, Inc., Gaithersburg, VA) according to the
manufacturer’s protocol. Stable transfectants were selected with
300 ug/ml G418 (Merck, Darmstadt, Germany).
Telomerase Activity Assay
Telomerase activity was measured using a TRAP-PCR-ELISA
assay kit following the manufacturer’s instructions (Roche, Basel,
Switzerland). Briefly, 2610
5 cells were suspended with lysis buffer,
and an equal amount of nuclear supernatant was used as a TRAP
template for PCR reaction. The reaction mixture was incubated at
25uC for 30 minutes, and then PCR was amplified for 35 cycles at
94uC for 30 s seconds and 59uC for 60 seconds. Then product was
mixed with a hybridization solution and incubated at 37uC for
1 hour, followed by washing and incubating for 30 minutes. It was
then chromogenized and the absorbance was detected.
TRF analysis
DNA was extracted using a DNA isolation kit (Roche, Basel,
Switzerland) and aliquots (2 mg) digested 2 hours with the
restriction enzymes RsaI and HinfI. Digested DNA fragments
were separated in 0.8% agarose gels and blotted onto positively
charged nylon membranes. Telomere restriction fragments were
revealed through hybridization with DIG-labeled telomere probe
and chemiluminescence detection.
Q-FISH for Cytogenetic Analysis
Chromosomes from colcemid arrest cells were prepared and
followed a standard Q-FISH technique [16] using the Telomere
PNA FISH/FITC kit (Dako Cytomation, USA). In brief, detached
cells were treated with 50 mmol/L KCl and fixed using 3:1
methanol/glacial acetic acid; then slides were prepared. Telomere
was detected using an FITC-conjugated peptide nucleic acid
(PNA) probe and counterstained with DAPI. Digital images were
captured under confocal microscopy at 606or 1206objectives.
Double Immunofluorescence
Cells were grown on glass coverslips and fixed in 4%
paraformaldehyde (PFA). After washing with PBS, the cells were
permeabilized using 0.1% Triton X-100 solution and blocked with
10% donkey serum. Following incubation with the primary
antibodies PML and TRF2, they were incubated with the
fluorescently labeled secondary antibodies Alexa Fluor 488, Alexa
Fluor 555/568 (invitrogen). Images were collected under confocal
microscopy and processed using Adobe Photoshop 7.0.
Western blotting
Western blotting was carried out as described previously [17].
Briefly, samples were analyzed by 12% SDS-PAGE, transferred to
nitrocellulose membranes, and probed with the primary antibodies
and secondary antibodies coupled to horseradish peroxidase, then
detected by the ECL chemiluminescent detection system (Amer-
sham, Piscataway, NJ).
Invasion and Migration Assay
The invasion and migration capability of T24 cells were
determined by the Transwell assay. For the invasion assay, 50 mL
of Matrigel (Sigma, Inc.) was applied to 8 mm-pore-size polycar-
bonate membrane filters (Corning, Inc., Corning, NY), the bottom
chamber of the apparatus containing DMEM with 20% FBS.
5610
3 T24, T24/PCI, and the 32
nd passage of T24/DN868A
(defined as surviving T24/DN868A in the following study) cells
were seeded with a serum-free medium, and then incubated for
48 hours at 37uC. Following incubation, the invaded cells attached
to the lower surface of the membrane were fixed by 4%
paraformaldehyde and stained with Giemsa. Cell numbers were
counted in three randomly chosen microscopic fields (106) per
membrane. The migration assay was carried out as described for
the invasion assay, with no coating of Matrigel.
Adhesion assay
Matrigel was dilute with serum-free DMEM at 1:20 and coated
onto bottom of 96-well plate. 1610
4 cells were harvest and seeded
in 96-well plate with serum-free medium and allowed to attach to
Matrigel. After 6 h, medium with unattached cells was removed
and MTT were added. 4 hrs of incubation later, DMSO was
added to solubilize the formazan crystals and the absorbance
(O.D.) at 590 nm was measured.
Soft Agar Colony Formation Assay
Thecolonyformationassaywasperformedasdescribedpreviously
[18]. Briefly, a total of 500 cells were suspended in 2 mL DMEM
containing 0.3% low melting agar and overlying the 2 mL base layer
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After incubation at 37uC with 5% CO2 in a humidified incubator for
14 d, colonies more than 50 cells were counted.
Tumorigenicity Assay in Vivo
Four to six weeks old nude athymic BALB/C mice (Shanghai
Experimental Animal Center, Shanghai, China) were used for the
tumorigenicity assay. Cells were harvested, washed, and resus-
pended in serum-free DMEM at the concentration of 1610
7 cells/
ml, and 1610
6 cells were injected subcutaneously. The mice were
sacrificed after 8 weeks to measure the tumor weight. Immuno-
histochemical staining was carried out as described previously
[19].
Statistical Analysis
All data analyses were done by the software SPSS 13.0 for
Windows. P,0.05 was regarded as the threshold value for
statistical significance.
Results
Telomerase activity in T24 cell clone expressing
dominant-negative (DN) hTERT
To constitutively inactivate hTERT, the human bladder cancer
cell line T24 with high TA was transfected with a plasmid
encoding DN-hTERT or empty vector PCI, and individual cell
clones were isolated by G418 screening for 7 weeks. TRAP-PCR-
ELISA analysis demonstrated that in T24/DN868A cells at the 3
rd
Figure 1. Telomerase activity in T24 cells with different
transfectants. Telomerase activity (TA) in T24 cells transfected with
various constructs was determined as described in Materials and
Methods (* P,0.05).
doi:10.1371/journal.pone.0027748.g001
Figure 2. Telomere length dynamics in T24 cells with different transfectants. A. TRF analysis of T24/DN868A cell clone with different
passage. DNA was extracted and performed using gel electrophoresis as described in Materials and Methods. B. Telomere length analysis by Q-FISH
on individual metaphase chromosomes from parental and transformed T24 subclones of different passages using FITC-labeled PNA telomere probes
(green) and counterstained with DAPI (blue). The intensity of green signals corresponds to the length of telomeres. a) U2OS cells; b) T24; c) T24/PCI;
d,f) T24/DN868A subclones of 8
th,2 4
th, and 27
th passages, respectively; g and h) T24/DN868A subclones of the 29
th and 32
nd passage, respectively
(1206). C. TA of cells at each time point when telomere length analysis was done. Histograms are representative of the TA in T24/DN868A versus
parental cell line.
doi:10.1371/journal.pone.0027748.g002
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(Fig. 1). Three clones with decreased TA were screened and
designated as T24/DN868A (M1,3). The empty vector-trans-
fected control cells were designated as T24/PCI.
Telomere length dynamics in T24 cell clone expressing
DN hTERT
To visualize telomere length of T24/DN868A cells at different
passage from earlier to later, TRF analysis was followed in these
three isolated clones. As shown in Fig. 2A, the median telomere
length was ,4.3 kb at 6
th passage of T24/DN868A-M1 and
continuous telomere shortening was observed until the 27
th
passage. This phenomenon was accompanied by a reduction of
the proliferation rate from 1 passage/2.5 per day to 1 passage/6
per day. After the 27
th passage, telomere elongation was appeared
again. A median length of ,6 kb with the occurrence of an
additional high molecular weight band at ,21 kb was displayed at
29
th passage. In addition, the proliferation rate of T24/DN868A
cells at this stage was increased to 1 passage/3 per day.
Furthermore, we stained the metaphasic chromosomes of T24/
DN868A cells with a telomeric PNA probe, and compared them
with those parental or control cells at the same passage. The
osteosarcoma cell line U2OS was used as an ALT-positive control
(Fig. 2B a) [20]. Fig. 2B shows Q-FISH analysis of one of the
clones. The very intense green signals at the end of chromosome
corresponded to the long telomeres. A detectable telomere FISH
signal could be seen at almost every chromosome end and in the
majority of nuclei in a different passage of parental T24 cells or
control cells T24/PCI; furthermore, the intensity of these signals
in both two cells was consistent (Fig. 2B b,c). After telomerase
inhibition, although the intensity of the green signal at each end of
chromosome or in the nuclei was consistent with the earlier
Figure 3. APBs status in different passages of hTERT-inactivated T24 cells. Double immunofluorescence analysis for APBs in hTERT-
inactivated T24 at different passages. Red spots represent PML, green spots represent TRF2, and yellow sparkles indicate the colocalizaiton of PML
with TRF2. APBs was absent in the T24, T24/PCI, and earlier passage of T24/DN868A cells but present in T24/DN868A cells at the 29
th and 32
nd
passage (606).
doi:10.1371/journal.pone.0027748.g003
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ally with each round of cell division until the 27
th passage, at which
point, the overall intensity of the fluorescent signal was lowest
(Fig. 2B d,f). After this passage, signals with different intensity
representing heterogeneous telomere length were seen at the end
of some chromosomes in T24/DN868A cells (Fig. 2B g,h). For
the other two tested T24/DN868A clones expressing DN hTERT,
both showed strong telomerase inhibition, but only one (T24/
DN868A-M3) displayed telomere length fluctuations as Fig. 2A
and B, while the other one (T24/DN868A-M2) went to cell death
and loss of the culture at the 16
th passage.
To analyze the nature of telomere elongation events, we
examined TA at each time point when Q-FISH was done in these
two viable cell clones. Inhibition of TA by DN hTERT was robust
and consecutive (up to the 32
nd passage), and the same low level of
TA was observed consecutively in T24/DN868A cells (Fig. 2C). It
is therefore unlikely that the remaining telomerase is the cause for
the observed telomere elongation.
APBs status in T24 cell clone expressing DN hTERT
APBs complex is a subset of promyelocytic leukemia (PML)
bodies containing telomeric DNA and telomere-binding proteins
such as TRF1 and TRF2. APBs may play an integral role in the
ALT mechanism, and are not found in mortal or telomerase-
positive cells [21]. Therefore, we detected the presence of APBs by
co-localization of PML with TRF2 in various T24 cells at different
passages compared with the osteosarcoma cell line U2OS. As
shown in Fig. 3, the co-localization of PML with TRF2 could not
be detected in the parental T24, T24/PCI cells, or earlier passages
of T24/DN868A cells. However, in the 29
th passage of T24/
DN868A cells, the yellow sparkles representing APBs were clearly
observed in some T24/DN868A cells. Moreover, an increase in
the overall number of APBs was observed in the 32
nd passage of
T24/DN868A cells. These results strongly indicate the presence of
an ALT-like mechanism of telomere stabilization in the subclone
of T24/DN868A cells from the 29
th passage. To distinguish the
late passage of T24/DN868A cells with characteristics of ALT-like
from earlier passage, all the T24/DN868A cells after the 29
th
passage were called as surviving T24/DN868A cells. One of each
surviving cell clone at the 32
nd passage was randomly used for the
following study.
Induction of EMT in T24 cells with telomerase inhibition
T24 is an E-cadherin deficient cell line which yet exhibits an
epithelial-like morphology [22]. During long term culture, we
found that T24 cells with telomerase inhibition gradually exhibited
a spindle-shaped, more elongated morphology and loose intercel-
lular junctions from the 25
th passage while T24 or T24/PCI cells
were still polyhedral and grew in a tightly connected manner,
which suggested that the cells may have undergone EMT (Fig. 4A).
To test this, detailed molecular characterization of EMT markers
of T24, T24/PCI, and different passage of T24/DN868A cells
(including 25
th,2 7
th, and 32
nd passage) were detected by Western
blot. Indeed, we observed the loss of epithelial markers including
CK18 and CK19 and increased levels of mesenchymal markers
and invasion-related proteins such as N-cadherin, Vimentin, and
MMP-2 in T24/DN868A cells from 25
th passage (Fig. 4B).
Decreased adhesion, increased migration, invasion, and
colony formation of surviving T24/DN868A cells in vitro
To investigate the potential involvement of telomere mainte-
nance and EMT in tumor development, we used surviving T24/
DN868A cells as a model to examine their cellular behaviors after
this conversion. Transwell assay results showed that both
migration and invasive potential of surviving T24/DN868A cells
were significantly increased compared with parental or control
cells (Fig. 5A).
In adhesion assay, Matrigel was used to coat the 96-well plate to
mimic the extracellular matrix (ECM). The O.D. value on behalf
of adhesive cells demonstrated that the adhesive capacity of
surviving T24/DN868A cell to Matrigel was markedly decreased
(Fig. 5B).
We further explored the impact of this conversion on the
clonogenicity of T24 cells. As expected, the soft agar assay
demonstrated that surviving T24/DN868A cells prominently
Figure 4. Cell morphology and analysis of EMT markers. A. cell morphology of T24, T24/PCI and T24/DN868A cells were observed under a
phase-contrast microscopy (206). Cell morphology changed from polygonal, epithelial structure (upper) to spindle-like, mesenchymal structure
(down). B. Western blot analysis of N-Cadherin, Vimentin, MMP-2, CK18, and CK19 levels in T24, T24/PCI, and different passage of T24/DN868A cells.
GAPDH was used as a loading control.
doi:10.1371/journal.pone.0027748.g004
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control T24/PCI cells (Fig. 5C).
Increased tumorigenesis of surviving T24/DN868A cells in
vivo
It has been shown previously that the ALT pathway does not
substitute for telomerase in the process of tumorigenesis in vivo
[23]; therefore, we established the tumor xenograft by subcuta-
neous injection of 1610
6 T24, T24/PCI, or surviving T24/
DN868A cells into 6–8-week-old nude mice (n=4 mice per
group). The tumor specimens were further analyzed by H&E
staining. Tumors developed in all of nude mice 3–4 weeks after
injection. Mice injected with surviving T24/DN868A cells showed
a sharply accelerated speed in tumor formation (Fig. 6A) with a
Figure 5. Progression capability of surviving T24/DN868A cells in vitro. A. Transwell assay for cell invasion and migration potential was
performed. B. Adhesion assay for adhesive ability was determined. C. Soft agar colony formation assay was performed. (*P,0.05, compared with
control cells).
doi:10.1371/journal.pone.0027748.g005
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3 after 8 weeks post
injection, whereas the mean tumor volume in mice injected with
T24 or T24/PCI cells were 90.3612.89 and 82.6610.07 mm
3,
respectively (Fig. 6B).
Histological staining showed that tumors derived from surviving
T24/DN868A cells were cord-like and more aggressive while
tumors derived from T24 or T24/PCI cells were rounded and less
malignant (Fig. 6C). To further confirm that surviving T24/
DN868A cells underwent EMT in vivo, immunohistochemical
examination was performed in tumor specimens from nude mice.
As the result, increased levels of N-cadherin and Vimentin in the
nucleus and the cytoplasm as well as reduced levels of CK18 and
CK19 between cell interfaces were observed in tissues derived
from surviving T24/DN868A cells (Fig. 6C).
Twist was activated to mediate EMT in surviving T24/
DN868A cells
Next we wondered the molecular mechanism by which T24/
DN868A conversion could modulate EMT. We examined many
transcription factors such as Slug, Twist, Snail, Smad4 and ZEB1
by RT-PCR. The primer sequences for RT-PCR were shown in
Table S1. As a result, only Slug and Twist were enhanced in
surviving T24/DN868A cells, whereas the other transcription
factors did not show obviously change (Fig. S1). Since Twist
involves in promotion of EMT [24], and is capable to overcome
oncogene-induced senescence in a variety of human cells [25], we
focused on its alteration in surviving T24/DN868A cells. As a
result, Twist was dramatically upregulated in these cells at both of
mRNA and protein levels (Fig. 7A and Fig. S2). Furthermore,
immunohistochemical staining of tissue samples exhibited a high
percentage of Twist staining in surviving T24/DN868A cells. In
addition to brownish dots representing Twist in the nucleus of a
majority of cells, a number of cells also showed both cytoplasmic
and nuclear staining (Fig. 7B). To further investigate the
significance of Twist in this EMT process, we knocked down
Twist with siRNA. Notably, down-modulation of Twist led to
decreased capability of migration and invasion in surviving T24/
DN868A cells (Fig. 7C and 7D). Meanwhile, these variations were
concomitant with the elevation of CK18, CK19, and the
suppression of N-cadherin, Vimentin, and MMP-2 in surviving
T24/DN868A cells (Fig. 7E).
Discussion
During the malignant progression of cancer cells, maintenance
of telomere length is a crucial prerequisite for their immortaliza-
tion [26], which is achieved by telomerase activity (TA) or
Figure 6. Tumorigenicity of surviving T24/DN868A cell in nude mice. A. Tumor growth assay. Cells were injected s.c. into the flank of nude
mice and tumor volume was measured weekly until 8 weeks after injection (*P,0.001, compared to T24 and T24/PCI cells). B. Representative tumors
isolated from T24, T24/PCI, and surviving T24/DN868A-injected nude mice. C. HE and immunohistochemical staining of EMT markers in tumors
derived from T24, T24/PCI, and surviving T24/DN868A cells, respectively (406).
doi:10.1371/journal.pone.0027748.g006
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is considered as a potential target for cancer therapy; however, the
situation is complicated by the existence of the ALT mechanism.
Current understanding of telomere length kinetics in the absence
of TA and subsequent engagement of the ALT pathway is
primarily based on mismatched repair-deficient human colon
cancer cells and laryngeal cancer cell line Hep-2 [28,29]. In this
work, DN hTERT was used to functionally inhibit TA in bladder
cancer T24, 5637, and 253J cell lines, and sequenced alteration of
telomere length was determined. Unfortunately, after transfection,
most of these bladder cancer cell lines went to death, and no single
cell clone could be cultured and passaged except for T24 cells. Our
data show that although the proliferation rate of T24 cells with
telomerase inhibition was retarded and the telomere length was
shortened in earlier passage, the features associated with ALT-like
pathway were observed during long-term culture. It is also worth
noting that the total level of PML and MRN complex increased
obviously, since more foci of MRE11, RAD50 and NBS1 were
observed in the nucleus in surviving T24/DN868A cells (Fig. S3).
While inhibiting telomerase resulted in either cell death or the
reappearance of TA as reported previously [30,31], our present
study reveals no obvious up-regulation of telomerase at each
passage based on the Q-FISH and TRF assay, suggesting that it is
unlikely that remaining telomerase is the main cause for the
observed telomere elongation in T24/DN868A cells. Instead, our
data demonstrate that ALT-like mechanism could be the
alternative way by which bladder cancer cells escape from
telomerase inhibition.
Activation of ALT results from sets of genetic changes which are
tumor-type specific, and many factors contribute to the selection of
this mechanism for telomere maintenance. T24 cells express a
mutant tumor suppressor protein p53 and a very low level of
MSH6 [32,33], which are considered as contributing factors for
ALT activation [34,35]. This may partly explain why among
many bladder cancer cell lines, only T24 escaped from the cell
crisis stage and continued to be alive.
Although ALT in tumors has not been studied extensively, it is
now becoming clear that cells of epithelial origin maintain their
telomeres via the telomerase pathway, whereas ALT is more
frequently present in tumors of mesenchymal origin [5]. EMT is a
process in which epithelial cells lose their epithelial phenotype and
acquire new characteristic features of mesenchyme [36]. Interest-
Figure 7. Twist mediated EMT in surviving T24/DN868A cells and tissues. A. RT-PCR and Western blot analysis of Twist expression in T24,
T24/PCI, and surviving T24/DN868A cells. B. Detection of Twist expression by immunohistochemical staining in nude mice tumor samples. C and D.
Surviving T24/DN868A cells were treated with siRNA specific to Twist, and analyzed for invasion and migration ability. E. Western blot analysis of EMT-
associated proteins.
doi:10.1371/journal.pone.0027748.g007
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EMT that typically accompanies tumor progression [15]. In
cataractous canine lens epithelial cells, the process of EMT also
involves TERT [37]. In this study, we have noticed that the
morphology of hTERT-inactivated T24 cells showed a gradual
mesenchymal change from 25
th passage during the consistent
culture as demonstrated by spindle shape and loss of intercellular
junctions. Reduced epithelial markers and increased mesenchymal
markers were displayed in both surviving T24/DN868A cells
before the on set of ALT-like characteristics, and tumor samples
derived from surviving cells, suggesting that EMT was activated to
bypass cell senescence as seen in other publications (13, 15). Based
on the different time of APBs appearance and EMT formation,
very likely, the pathways leading to these changes may be different.
Telomerase and ALT are thought to be functionally inequitable
in promptingtumor progression, but it remains contradictory which
pathway is more aggressive. Some studies suggest that the ALT
pathway, at least in some cell lines, does not functionally substitute
for telomerase with respect to tumorigenicity and metastatic lesions
[38]. In present study, we have examined the progression ability of
surviving T24/DN868A cells. Compared with those of parental
T24 or control cells, motility, invasion, and clone formation ability
in vitro and tumorigenicity in vivo of surviving T24/DN868A cells
were significantly enhanced, whereas adhesive ability of surviving
T24/DN868A cells in vitro was inhibited, thus providing strong
support that this fully malignant phenotype was triggered in
surviving T24/DN868A cells with EMT.
The basic helix-loop-helix (bHLH) transcription factor Twist is
a prompter of EMT [39], and its overexpression is significantly
correlated with the stage and grade of human bladder tumor [40].
In the context of carcinogenesis, Twist can simultaneously
suppress the senescence response and induce EMT [41]. In the
present study, we found that Twist is overexpressed in surviving
T24/DN868A cells from 24
th passage, and further aggregated in
animal bladder tumor tissues. Consistently, depletion of Twist
reduces the progression ability of surviving T24/DN868A and
induces mesenchymal-to-epithelial (MET)-like change. Therefore,
activation of EMT under telomerase inhibition requires the
collaboration of the Twist-signaling pathway in bladder cancer.
Taken together, our data show that features associated with
ALT-like mechanism and EMT could be induced after telomerase
inhibition in bladder cancer cells with certain genetic background.
Decreased adhesion ability in vitro, increased capabilities of
migration, invasion, and colony formation in vitro and tumorigen-
esis in vivo of surviving T24/DN868A cells is associated with EMT
induction, which is mediated by the activation of the Twist-
signaling pathway. The progression of bladder cancer with ALT-
like pathway after telomerase inhibition and the activation of
EMT suggest a novel possible mechanism of drug resistance to
anti-telomerase therapy in clinic bladder cancer patients.
Supporting Information
Figure S1 Expression of transcriptional factors was detected by
RT-PCR. ß-actin was used as an internal standard. Three
experiments were performed independently.
(TIF)
Figure S2 Expression of Twist in different passage of T24/
DN868A was detected by Western blot. GAPDH was used as a
loading control.
(TIF)
Figure S3 MRN status in surviving T24/DN868A cells. Double
immunofluorescence analysis with mouse anti-PML and rabbit
anti-MRE11, RAD50 or NBS1 in surviving T24/DN868A cells
was shown. Red spots represent MRN components, green spots
represent PML, and yellow sparkles indicate the colocalization of
PML with MRN. Accumulated MRN spots in the nucleus were
observed in surviving T24/DN868A cells, and most of them were
colocalized with PML sparkles (606).
(TIF)
Table S1 The primer sequences for RT-PCR.
(DOC)
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